Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.38 Analyst target: $24.33 Upside: 619.82%
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.